



Extramural Meeting 2024

Patient Based Cases 2023

Yvonne Zoet
Eurotransplant Reference Laboratory
LEIDEN







Patient case 2023-01: Recipient information



A 5 years old boy with blood group B pos was registered on the kidney waitlist

Recipient HLA type: A*02:05, A*11:01, B*50:01, B*54:01, C*01:02, C*06:02, DRB1*07:01, DRB1*12:02,

DRB3*03:02, DRB4*01:03, DQB1*02:02, DQB1*03:01, DQA1*02:01, DQA1*06:01,

DPB1*03:01, DPB1*04:01, DPA1*01:03, DPA1*02:02

Antibody information:

No immunizing events

2 sera were tested with a 3-month time interval before waitlist registration:

CDC: negative

LMX positive for Class II

Luminex SA shows Class II specificities





Lifecodes	DR9	DR4	DR7	DR52	DR103	DR1	DR16	DR15	DR14	DR12	DR13	DR3	DR10
Serum 1	6263	5684	5527	4574	3031	2970	2838	2687	2486	2451	2336	2311	1806
Serum 2	1739	1719	1615	1424	604	674	582	593	578	*	*	*	*

Values in background adjusted MFI, *Values below MFI 500 are not depicted

DP3	1	2	5700,7
DR9	2	0	2639,65
DR4	4	1	2172,21
DR7	1	0	2015,34
DR12	1	1	1933,9
DR52	1	2	1530,94
DR103	1	0	1490,37

One lambda serum 1

DP3	1	2	4313,6
DR12	1	1	1664,7
DR9	2	0	1416,56
DR4	5	0	1365,68
DQ6	1	5	1284,56
DQ7	2	3	1253,8
DR1	1	1	1216,76

One lambda serum 2

Found in both sera/test kits Patient's HLA type

Patient case 2023-01: Definition of Unacceptable Antigens?



9/49 centers defined one or more unacceptable antigens:

Specificity	DR4	DR9	DR52
Frequency	8	8	4

Specificity	DR1	DR15	DR16	DR17	DR18	DR10	DR11	DR13	DR14	DR51	DR53
Frequency	3	3	3	3	3	3	3	3	3	3	3

Specificity	DR12	DP3	DR7	DR8
Frequency	2	2	1	1

Found in both sera/test kits Patient's HLA type

Most other centers remarked that in this pre-transplantation situation without known immunizing events the MFI values are overall too low for unacceptable antigen definition

Patient case 2023-01: Additional testing?



- Follow up: repeat antibody testing after 3-6 months
- Repeat the test on treated serum: presorb, serum cleaner, EDTA, Adsorb-Out, freezing and thawing
- Auto crossmatch: By CDC and or FCM
- Confirmation of non-specific reactivity: Crossmatch (flow, B-cells, T-cells) for specific allo-reactivity or B-cell screening
- Repeat HLA typing of patient; HLA-typing of mother
- Allocation Crossmatch on separated T- and B-cells
- SAB complement fixing antibodies

Explanations for the presence of (false positive) antibodies



- Medication/Therapy: IVIG, therapeutic antibodies, or other medication?
- Underlying (autoimmune) disease
- Recent infections/vaccinations
- Antibodies against denatured HLA/structures of artificially developed bead array antigens/recombinant HLA molecules
- It is not uncommon to see positive reactions in SAB tests in young children without immunizing events
- In the One Lambda test often an unspecific DP1 signal is seen

Patient case 2023-01: ETRL and center remarks



There is no explanation for the antibodies found.

Some of the antibody specificities were listed:

A24, DR1, DR15, DR16, DR17, DR18, DR4, DR11, DR12, DR13, DR14, DR7, DR9, DR10, DR52 No unacceptable antigens were listed

The patient was transplanted with a deceased donor kidney.

HLA-type of the donor: A2, A68, A28, B7, B8, Bw6, Cw7, DR15, DR2, DR7, DR51, DQ6, DQ1, DQ9, DQ3, DQA-01, DQA-02, DP-0401, DP-13, DPA-01, DPA-02

Patient case 2023-02



The male recipient, aged 45 years, blood group B pos, returned to the kidney waitlist after failure of the first graft

Recipient HLA type:

A*02:01, A*A24:02 B*07:02, B*50:01, C*06:02, C*07:02 DRB1*07:01, DRB4*01:03, DQB1*02:01, DQA1*02:01, DPB1*04:01

Immunizing events:

Cadaveric donor kidney in 2004, which failed in 2018 Available donor HLA type: A3, A9, A23, B35, B21, B50, DR5, DR11, DR7, DQ3, DQ7, DQ2

Antibody information:

Luminex screen: negative for class I, positive for class II CDC screening: 8% with and without DTT Luminex SAB Class I results were negative Luminex SAB II results from recent serum

Patient case 2023-02; Antibody profile



Spec	DQA1*04:01	DQA1*06:01	DQA1*05:01	DQA1*03	DQA1*01	DQA1*02:01
MFI	20667	20610	20076	19600	19356	19259

Spec	DQB1*03	DQB1*04	DQB1*06	DQB1*05	DQB1*02
MFI	20713	20616	20245	18337	13673

Spec	DRB1*09	DRB1*01:03	DRB1*11	DRB1*14	DRB1*13:01	DRB1*12:02	DRB1*04:02
MFI	8632	6760	3043	2876	2863	2265	2082

Note the following DQA-DQB combinations:

	MFI
DQA1*02:01 DQB1*02:02	14437
DQA1*02:01 DQB1*02:01	1438

Explanation of the antibody reactivity pattern



- By the donor HLA-type. Transplantation took place in 2004
 No donor material was left to perform a high-resolution typing
- The most likely donor class II typing would be: DR11-DQB1*03:01-DQA1*05:05 DR7-DQB1*02:02-DQA1*02:01
- Antibodies against DQ7 (immunizing antigen), DQ8, DQ9, DQ5, DQ6 and DQ4 could all be explained by a shared eplet (46VY)
- DQA1*05:01 immunization could be explained by the donor DQA1*05:05. DQA1*05:01 and DQA1*05:05 have identical amino acids present on solvent accessible positions
- Antibodies against DQB1*02:02 could be explained by the proposed DQ2 typing of the donor.
- DR antibodies are more difficult to explain by the donor HLA type, only DR11 antibodies can be explained.

Patient case 2023-02: Remarks



Until recently high resolution typing of cadaveric donors was not available

Translating the donor HLA-type into the most likely high-resolution HLA-type as well as imputation or linkage for the DQA chain, may help to understand the immunization status of a patient

Please be aware that in reality the HLA-type may be different

Try to obtain as much immunological information as possible

Patient case 2023-03: Recipient information



Male recipient aged 43 years, blood group A pos, transplanted with a deceased donor kidney in 2014 The organ failed in 2018

Recipient HLA type: A31, A33, B18, B72, Bw6, Cw2, Cw7, DR4, DR10, DR53, DQ5, DQ8, DQA-01, DQA-03, DP-03, DP-0401, DPA-01

HLA type of the failed donor kidney:

A3, B7, B35, Bw6, Cw4, Cw7, DR4, DR12, DR52, DR53, DQ7

Antibody information:

Recent Luminex screen: negative for class I, positive for class II

Recent autologous crossmatch: positive

No CDC antibodies; SAB antibodies: see following slide

Crossmatch on unseparated speen cells without DTT: Positive; with DTT: Negative HLA type donor offer: A3, B7, B37, Bw4, Bw6, Cw6, Cw7, DR4, DR10, DR53, DQ5, DQ1, DQ8, DQ3

Patient case 2023-03 Immunology



Recipient HLA type:

A31, A33, B18, B72, Bw6, Cw2, Cw7, DR4, DR10, DR53, DQ1,DQ5, DQ3,DQ8, DQA-01, DQA-03, DP-03, DP-0401, DPA-01

First donor's HLA type:

A3, B7, B35, Bw6, Cw4, Cw7, DR4, DR12, DR52, DR53, DQ3, DQ7

Current Donor offer HLA type:

A3, B7, B37, Bw4, Bw6, Cw6, Cw7, DR4, DR10, DR53, DQ5, DQ1, DQ8, DQ3

Green: match

Blue: mismatch without proven antibodies (CDC or Luminex SA)

Orange: repeated mismatch

Unacceptable Antigens as defined by the recipient's laboratory: A2, A28, B8, DR3, DR6

Patient case 2023-03: Unacceptable antigens



	A2	A28	B8	DR3	DR6
Historic MFI (One Lambda)	4946	3987	3490	4532	2533
Current MFI (Immucor)	181	184	114	145	298

MFI: raw values

No unacceptable antigens are present in the donor's phenotype according to single antigen data: A31, A33, B18, B72, Bw6, Cw2, Cw7, DR4, DR10, DR53, DQ1,DQ5, DQ3,DQ8, DQA-01, DQA-03, DP-03, DP-0401, DPA-01

15 centers indicate that the repeated mismatches are considered unacceptable

Patient case 2023-03: Discussion



Crossmatch:

- Negative with DTT
- Autologous crossmatch is positive
 Indicates IgM antibodies (no contraindication)

Patient case 2023-03: Discussion



Repeated mismatches

- No antibodies directed against the repeated mismatches
- Standard risk
 (data Dave Roelen; presented at the annual ET meeting in 2023, available via https://my.eurotransplant.org/organization/?target=annual-meeting)

Request: New cases!



Preferably concerning (recipients awaiting) deceased donor kidney transplantations

For example:

- for recipients with an aberrant antibody profile
- with unexpected crossmatch outcomes
- for a recipient waiting longer than average
- with interventions done to facilitate transplantation
- and other.....

Please send a short information to the ETRL: etrl@eurotransplant.org

- All recipient, donor and center data will by anonymized -

Thanks to the labs who already made cases available!





Thank You

For participating in the patient-based cases EPT



The ETRL-team etrl@eurotransplant.org



